bezeq speed test
דרכון פורטוגלי
הוצאת דרכון פורטוגלי
אי ביי ישראל, עליי אקספרס
ivory באר שבע גרנד קניון, גובל תרגום, גוגל תרגם
ויאגרה מקורית ללא מרשם
turboforex отзывы
турбофорекс отзывы

Board of Directors

Glen Bradley, PhD
Chairman of the Board

максимаркетс вход
отзывы форекс клуб
Dr. Glen Bradley became one of Refocus Group’s directors and Chairman of the Board in 2003. His comprehensive background in pharmaceuticals and laser vision correction has made him a respected resource in the health care industry. He is a current member of the board of Intuity Medical (glucose monitoring) and a former board member of AerovectRx (pulmonary drug delivery), Biofisica (wound healing), Spectra Physics (lasers), and Summit Technology (laser vision correction).

Previously, he served as President of the Contact Lens Institute and the Swiss American Chamber of Commerce for the Southeastern United States. Dr. Bradley was the Chief Executive Officer of CIBA Vision—the Ophthalmic Division of Novartis—from 1990 until 2003. Prior to CIBA Vision, he headed the USA Electronic Equipment Group for CIBA-Geigy and previously was a senior manager in CIBA-Geigy’s Plastics & Additives and Agricultural Divisions.

Dr. Bradley has a PhD in Chemical Engineering from Louisiana State University and an MBA from the University of Connecticut.

Mike Judy

Mike Judy joined Refocus Group in 2013 as the Chief Executive Officer, bringing with him 30 years of experience in the ophthalmology industry. Prior to joining Refocus, he most recently served as Chief Commercial Officer for AcuFocus, leading the sales and marketing team as they introduced the KAMRA™ corneal inlay.

Mr. Judy’s previous experience also includes his role as the Vice President of Global Surgical Marketing for Bausch and Lomb, where he was responsible for the cataract and refractive businesses. He joined B&L through the acquisition of Eyeonics, manufacturer of the Crystalens®. At Eyeonics, Mr. Judy led the sales and marketing team that captured the number one market share position in the premium IOL market. He has also served on various industry boards throughout his career.

Mr. Judy has a BA from Princeton University.

Harry Jacobson, MD

Dr. Harry Jacobson has been a director of Refocus Group since 2011. His background is rich with medical, academic, and investment experience, giving him unique insight to contribute to the Refocus board. He is currently chairman of MedCare Investment Funds, one of Refocus Group’s major investors. Dr. Jacobson is also a principal in TriStar Technology Ventures—a fund investing in early-stage health care opportunities—and founder and Managing Partner of the Health Care Investment Group.

Previously, Dr. Jacobson was a cofounder of the dialysis services company Renal Care Group. Currently, He serves on the boards of Merck, Kinetic Concepts, and Ingram Industries. He spent 7 years on the faculty at University of Texas Southwestern and 25 years at Vanderbilt University. From 1997 to 2009, Dr. Jacobson led the Vanderbilt University Medical Center as the Vice Chancellor for Health Affairs. He also published more than 100 scientific papers, edited a major textbook in Nephrology, and served 2 years as a physician in the Army’s burn unit at Fort Sam Houston. In 2002, Dr. Jacobson’s was elected to the National Academy of Science’s Institute of Medicine for his contributions to medicine.

Dr. Jacobson has an MD from the University of Illinois, completed his medical residency at Johns Hopkins, and received specialty training in Nephrology at UT Southwestern Medical Center.

Thomas Lyles, Jr.

Thomas Lyles has served as Director of Refocus Group since 2005. As a member on a number of boards within the health care industry, he brings a solid legal and investment background to Refocus Group. In addition to his position on the Refocus board, Mr. Lyles serves as an advisory director to Majesty Hedge Funds, and sits on the boards of CeloNova BioSciences, Ambulatory Services of America, digiChart, MedSolutions, Informatics Corporation of America, and Outpatient Imaging Affiliates.

Mr. Lyles has served as president (since 1998) and general counsel (since 1990) of Mission City Management, where he has managed a multi-company investment portfolio, including public and large private companies. He has also served as president of MedCare Investment Funds since 2003. From 1984 to 1989, he was a senior associate with the law firm Haynes and Boone. Prior to attending law school, Mr. Lyles was an accountant with KPMG.

Mr. Lyles received his JD from SMU Law School in 1983 and his degree in accounting from Texas A&M University in 1979.

Thomas M. Loarie

Thomas Loarie has served as a director of Refocus Group since 2014. Mr. Loarie is also the Executive Chairman for eMedonline, Chairman for Silicon BioDevices, Inc., a board member for Clarity Medical Systems, and an advisor/mentor for two COOs and other start-ups. He gained extensive hands-on and global operating experience in all business functions as a turnaround specialist in AHSC’s Medical Specialty and International Groups. Since 1984, he has led venture-backed medical start-ups from concept to commercialization and has raised more than $200 million in the private and public markets.

In addition to his participation on several boards, Mr. Loarie serves on the Dean’s Council for Jacobs School of Engineering at University of California San Diego. He is also a columnist for the Catholic Business Journal and is one of Amazon’s Top 1000 Reviewers. Mr. Loarie has served as assistant professor of surgery for Creighton University Medical School, board member of the California Healthcare Institute, and trustee of the Graduate Theological Union. He has lectured and written extensively on medical technology innovation and its implications for health care public policy, with articles in the Wall Street Journal, Royal Academy of Engineering World Technology Update, the Journal of Applied Manufacturing Systems, & the Journal of Refractive Surgery.

Mr. Loarie has an MBA from the University of Chicago and received his BSME from the University of Notre Dame.

Grady Schleier

Grady Schleier has served as a director of Refocus Group since 1998. He is currently a cofounder and Chief Executive Officer of Design Partners International, a distributor of lighting fixtures to the construction industry.

From 2002 to 2007, Mr. Schleier was the Chief Executive Officer and co-chairman of Chemlink Laboratories, and he continues to serve on the board. Chemlink Laboratories is primarily engaged in the development, manufacture, and distribution of effervescent tablets and granule formulations for use in cleaning, disinfecting, and sterilization applications. From 1999 until joining Chemlink, Mr. Schleier served as the Senior Vice President, Chief Financial Officer, and Treasurer of Avatex Corporation.

Mr. Schleier is a CPA and received his MBA from Southern Methodist University, and he has a BBA from the University of Texas at Austin.

Donald Phillips

Mr. Phillips has over 34 years of investment management experience managing large pools of pension assets in the capacity of both a limited and a general partner. Prior to founding WP Global Partners in 2005, Mr. Phillips was the Chief Investment Officer and CEO for WestAM (U.S.), a subsidiary of WestLB, a large German Bank. At WestAM he directed the investment strategy and oversaw the firm’s approximately $3 billion portfolio in commitments to private equity funds, real estate, and direct investments. In addition, he was a member of WesAM’s Board of Directors. He assumed these roles at WestAM in 2000 when they acquired the private equity business of Forstmann-Leff International, Inc. Mr. Phillips had been President of Forstmann-Leff from 1997 to 2000, and during that period was responsible for the strategic process of building and managing the global investment management firm. Forstmann-Leff International is a multi-asset class institutional investment firm with offices in Chicago, New York, and Liverpool, England. The firm has been managing assets for high net worth individuals, pension funds and other institutions for almost 30 years with assets under management that exceed $85 billion. The styles of managing assets include U.S. mid-cap value oriented equities, fixed income that includes core U.S., high yield and global portfolio management in addition to the management of private placement or alternative asset classes for large institutions

From 1990 until 1997, Mr. Phillips was Chairman of Equity Institutional Investors where he was responsible for the formation of four real estate funds with equity commitments of over $2.5 billion. These funds have been subsequently consolidated into a public company, Equity Office Properties that was sold to Blackstone for $50 billion in 2007. During the same time period at Equity Group Investments, he was instrumental in establishing the $1.1 billion Zell/Chilmark Fund to buy good companies with bad balance sheets. The fund acquired seven public and private companies that have combined sales of $8 billion and over 50,000 employees. Also, Mr. Phillips was President of Capstone Holdings Corp., a publicly traded insurance holding company and board member of other publicly traded companies within the Equity Group.

His previous positions include eight years as the Chief Investment Officer for Ameritech Corporation, where he managed all asset classes of Ameritech’s $15 billion pension fund. The Ameritech fund was an early investor in private equity, venture capital and commercial real estate. His efforts at Ameritech were recognized by the Institutional Investor Magazine, which sleected him as one of the country’s top 10 pension fund managers. Recently, he was awarded the Richard J. Daley Medal by the Illinois Venture Capital Association which recognizes “extraordinary contributions to the Illinois Economy resulting from private equity investing.” He has an M.B.A. in finance from Northern Illinois University and a B.A. in business from Western Illinois University